现有乙型肝炎多表位疫苗在中国人群中的理论免疫效果评价

Valuation of theoretical immune response status of HBV multi-epitope vaccines in existence in the population of China

目的预测现有乙型肝炎(HBV)多表位疫苗在中国的理论免疫应答率,并做出评价。方法利用"中国多表位疫苗设计的HLA-Ⅰ积累表型频率空间预测系统"计算现有的HBV表位DNA疫苗所涉及的HLA-A、B限制性表位组合在中国人群中的累积表型频率(CPF),得出理论免疫应答率,并绘制CPF预测等值线图,给出评价。结果现有各HBV多表位疫苗对中国人群的理论免疫应答率偏低,仅较多表位组合的疫苗理论免疫应答率高。现有HBV多表位疫苗存在不同方面的问题:大部分此类疫苗对中国人群的理论免疫应答率低;少数此类疫苗理论免疫应答率高,但为较多表位的组合,不符合多表位疫苗设计的原则,并没有用最少的表位组合达到最高的免疫应答率。结论现有的几种主要的HBV多表位疫苗并不能较好地符合中国人群的特点,效果不佳。

Objective To predict the theoretical immune response status of HBV multi-epitope vaccines and valuate its effect in the population of China.Methods Cumulative phenotypic frequency（CPF）of HBV multi-epitope vaccines was calculated by the system,Forecasting System of Theoretical Immune Response Rate of HLA-A-B Loci Restricted Multi-epitope Vaccine in the Chinese Population,and thus their theoretical responder status in the Chinese population was evaluated.Results The problems of HBV multi-epitope vaccines had already been found in the two aspects.On the one hand,the theoretical responder status of most HBV multi-epitope vaccines are low in the Chinese population,on the other hand,vaccines with high theoretical responder status are combinations of five or more epitopes,which is unnecessary and uneconomical.Conclusion HBV multi-epitope vaccines have already been observed do not achieve the ideal level,and new HBV multi-epitope vaccines should be worked on.